Cargando…
Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection
The diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) in differentiating hepatocellular carcinoma (HCC) from other hepatic malignancies has not been investigated in Chinese patients with chronic liver disease from hepatitis B virus (HBV) infection. The aim of this study...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416181/ https://www.ncbi.nlm.nih.gov/pubmed/31999940 http://dx.doi.org/10.17305/bjbms.2019.4576 |
_version_ | 1783569278943887360 |
---|---|
author | Shao, Shuo Liang, Yingying Kuang, Sichi Chen, Jingbiao Shan, Qungang Yang, Hao Zhang, Yao Wang, Bin Fowler, Kathryn J. Wang, Jin Sirlin, Claude B. |
author_facet | Shao, Shuo Liang, Yingying Kuang, Sichi Chen, Jingbiao Shan, Qungang Yang, Hao Zhang, Yao Wang, Bin Fowler, Kathryn J. Wang, Jin Sirlin, Claude B. |
author_sort | Shao, Shuo |
collection | PubMed |
description | The diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) in differentiating hepatocellular carcinoma (HCC) from other hepatic malignancies has not been investigated in Chinese patients with chronic liver disease from hepatitis B virus (HBV) infection. The aim of this study was to evaluate the accuracy of the LI-RADS version 2018 in differentiating HCC, intrahepatic cholangiocarcinoma (ICCA), and combined HCC-cholangiocarcinoma (cHCC-CCA) in Chinese patients with HBV infection. Seventy consecutive HBV-infected patients with ICCA (n = 48) or cHCC-CCA (n = 22) who underwent contrast-enhanced magnetic resonance imaging (CE-MRI) between 2006 and 2017 were enrolled along with a comparison cohort of 70 patients with HCC and CE-MRI-matched for tumor size (10–19 mm, 20–30 mm, 31–50 mm, and >50 mm). Imaging feature frequencies for each tumor type were compared using Fisher’s exact test. The classification accuracy of LR-5 and LR-M was estimated for HCC versus non-HCC (ICCA and cHCC-CCA). The interobserver agreement was good for LI-RADS categories of HCC and moderate for non-HCC. After consensus read, 66 of 70 (94%) HCCs were categorized LR-5 (including tumor in vein [TIV] with LR-5), while 42 of 48 (88%) ICCAs and 13 of 22 (59%) cHCC-CCAs were categorized LR-M (including TIV with LR-M) (p < 0.001). Thus, assignment of LR-5 provided 94% sensitivity and 81% specificity for HCC. LR-M provided 79% sensitivity and 97% specificity for non-HCC (ICCA and cHCC-CCA); and the sensitivity and accuracy were lower in differentiating HCC from non-HCC (tumor size <20 mm). LI-RADS v2018 category 5 and M reliably differentiated HBV-related HCC from ICCA. However, a substantial proportion of cHCC-CCAs were categorized LR-5 rather than LR-M. While management is controversial for these combined tumors, accurate prospective differentiation is desired for optimal treatment. |
format | Online Article Text |
id | pubmed-7416181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
record_format | MEDLINE/PubMed |
spelling | pubmed-74161812020-08-13 Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection Shao, Shuo Liang, Yingying Kuang, Sichi Chen, Jingbiao Shan, Qungang Yang, Hao Zhang, Yao Wang, Bin Fowler, Kathryn J. Wang, Jin Sirlin, Claude B. Bosn J Basic Med Sci Research Article The diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) in differentiating hepatocellular carcinoma (HCC) from other hepatic malignancies has not been investigated in Chinese patients with chronic liver disease from hepatitis B virus (HBV) infection. The aim of this study was to evaluate the accuracy of the LI-RADS version 2018 in differentiating HCC, intrahepatic cholangiocarcinoma (ICCA), and combined HCC-cholangiocarcinoma (cHCC-CCA) in Chinese patients with HBV infection. Seventy consecutive HBV-infected patients with ICCA (n = 48) or cHCC-CCA (n = 22) who underwent contrast-enhanced magnetic resonance imaging (CE-MRI) between 2006 and 2017 were enrolled along with a comparison cohort of 70 patients with HCC and CE-MRI-matched for tumor size (10–19 mm, 20–30 mm, 31–50 mm, and >50 mm). Imaging feature frequencies for each tumor type were compared using Fisher’s exact test. The classification accuracy of LR-5 and LR-M was estimated for HCC versus non-HCC (ICCA and cHCC-CCA). The interobserver agreement was good for LI-RADS categories of HCC and moderate for non-HCC. After consensus read, 66 of 70 (94%) HCCs were categorized LR-5 (including tumor in vein [TIV] with LR-5), while 42 of 48 (88%) ICCAs and 13 of 22 (59%) cHCC-CCAs were categorized LR-M (including TIV with LR-M) (p < 0.001). Thus, assignment of LR-5 provided 94% sensitivity and 81% specificity for HCC. LR-M provided 79% sensitivity and 97% specificity for non-HCC (ICCA and cHCC-CCA); and the sensitivity and accuracy were lower in differentiating HCC from non-HCC (tumor size <20 mm). LI-RADS v2018 category 5 and M reliably differentiated HBV-related HCC from ICCA. However, a substantial proportion of cHCC-CCAs were categorized LR-5 rather than LR-M. While management is controversial for these combined tumors, accurate prospective differentiation is desired for optimal treatment. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2020-08 /pmc/articles/PMC7416181/ /pubmed/31999940 http://dx.doi.org/10.17305/bjbms.2019.4576 Text en Copyright: © The Author(s) (2020) http://creativecommons.org/licenses/by/4.0 This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | Research Article Shao, Shuo Liang, Yingying Kuang, Sichi Chen, Jingbiao Shan, Qungang Yang, Hao Zhang, Yao Wang, Bin Fowler, Kathryn J. Wang, Jin Sirlin, Claude B. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection |
title | Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection |
title_full | Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection |
title_fullStr | Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection |
title_full_unstemmed | Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection |
title_short | Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection |
title_sort | diagnostic performance of li-rads version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis b virus infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416181/ https://www.ncbi.nlm.nih.gov/pubmed/31999940 http://dx.doi.org/10.17305/bjbms.2019.4576 |
work_keys_str_mv | AT shaoshuo diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT liangyingying diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT kuangsichi diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT chenjingbiao diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT shanqungang diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT yanghao diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT zhangyao diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT wangbin diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT fowlerkathrynj diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT wangjin diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection AT sirlinclaudeb diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection |